An altered HLA-A0201-restricted MUC1 epitope that could induce more efficient anti-tumor effects against gastric cancer
H Yu, C Ye, J Li, C Pan, W Lin, H Chen, Z Zhou… - Experimental Cell …, 2020 - Elsevier
MUC1 is a tumor-associated antigen (TAA) overexpressed in many tumor types, which
makes it an attractive target for cancer immunotherapy. However, this marker is a non …
makes it an attractive target for cancer immunotherapy. However, this marker is a non …
Identification of three non‐VNTR MUC1‐derived HLA‐A*0201‐restricted T‐cell epitopes that induce protective anti‐tumor immunity in HLA‐A2/Kb‐transgenic mice
LC Heukamp, SH van der Burg… - … journal of cancer, 2001 - Wiley Online Library
The human epithelial mucin MUC1 is over‐expressed in more than 90% of carcinomas of
the breast, ovary, and pancreas as well as in some other tumours, making it a potential …
the breast, ovary, and pancreas as well as in some other tumours, making it a potential …
Identification of an HLA-A* 0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy
J Wu, J Wei, K Meng, J Chen, W Gao… - …, 2009 - Taylor & Francis
Recent research has indicated that MUC4 plays an important role in the development of
many tumors and may prove useful as a novel cancer immunotherapy target. We aimed to …
many tumors and may prove useful as a novel cancer immunotherapy target. We aimed to …
The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours
Summary Mucin antigen 1 (MUC1) is overexpressed on various human adenocarcinomas
and haematological malignancies and has long been used as a target antigen for cancer …
and haematological malignancies and has long been used as a target antigen for cancer …
Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer
J Hong, G Guo, S Wu, S Lin, Z Zhou… - Journal of Leukocyte …, 2022 - academic.oup.com
The efficacy of conventional treatments for pancreatic cancer remains unsatisfactory, and
immunotherapy is an emerging option for adjuvant treatment of this highly deadly disorder …
immunotherapy is an emerging option for adjuvant treatment of this highly deadly disorder …
Identification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring
T Scheikl-Gatard, C Tosch, F Lemonnier… - Journal of Translational …, 2017 - Springer
Background The success of immunotherapeutics in oncology and the search for further
improvements has prompted revisiting the use of cancer vaccines. In this context, knowledge …
improvements has prompted revisiting the use of cancer vaccines. In this context, knowledge …
Identification of HLA-A2–restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
P Brossart, KS Heinrich, G Stuhler… - Blood, The Journal …, 1999 - ashpublications.org
The tumor-associated antigen MUC1 is overexpressed on various hematological and
epithelial malignancies and is therefore a suitable candidate for broadly applicable vaccine …
epithelial malignancies and is therefore a suitable candidate for broadly applicable vaccine …
Novel breast‐tumor‐associated MUC1‐derived peptides: Characterization in Db−/− × β2 microglobulin (β2m) null mice transgenic for a chimeric HLA‐A2.1/Db‐β2 …
L Carmon, KM el‐Shami, A Paz… - … journal of cancer, 2000 - Wiley Online Library
The MUC1 protein was found to be up‐regulated in a spectrum of malignant tumors. T‐cell
responses to the MUC1 extracellular tandem repeat array (TRA) were observed in murine …
responses to the MUC1 extracellular tandem repeat array (TRA) were observed in murine …
Identification of HLA-A* 0201-and A* 2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer
S Yamazoe, H Tanaka, T Iwauchi, M Yoshii, G Ito… - Pancreas, 2011 - journals.lww.com
Objectives: Mucin 5AC (MUC5AC) was previously identified as being expressed in most
pancreatic ductal adenocarcinomas. We studied the significance of MUC5AC expression for …
pancreatic ductal adenocarcinomas. We studied the significance of MUC5AC expression for …
Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms …
MM Soares, V Mehta, OJ Finn - The Journal of Immunology, 2001 - journals.aai.org
Low-frequency CTL and low-titer IgM responses against tumor-associated Ag MUC1 are
present in cancer patients but do not prevent cancer growth. Boosting MUC1-specific …
present in cancer patients but do not prevent cancer growth. Boosting MUC1-specific …